The global Transcatheter Aortic Valve Replacement (TAVR) market size was valued at USD 2.6 billion in 2017. It is anticipated to rise at a CAGR of 21% over the forecast period 2020-2026. Rising number of patients across the globe suffering from cardiovascular diseases is escalating the growth. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure and known as transcatheter aortic valve implantation (TAVI). It can be used in the treatment of aortic stenosis. Simply put, the procedure removes the old and damaged valve and inserts the replacement valve into aortic valve’s position. This procedure is approved by FDA and is basically for people with symptomatic aortic stenosis.
The TAVR is performed using two different approaches that enables the surgeon to decide between the best and safe practice to access the valve. In the first approach, the TAVR procedure is initiated by entering through a femoral artery, usually called as transfemoral approach, which does not incorporate any surgical incision in the chest. In the second approach, TAVR is generally performed using a minimally invasive surgery with a small incision in the chest, arriving via a large artery in the chest or through left ventricle, which is usually known as transapical approach.